6,000‑Share Rule 144 Sale by NewAmsterdam Pharma (NASDAQ: NAMS)

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. reported a Rule 144 notice for a sale of 6,000 ordinary shares. The sale was reported by Johannes Jacob Pieter Kastelein with a transaction date of 01/05/2026 and proceeds shown as $199,500.

Insights

Securities Compliance Attorney

Rule 144 sale of 6,000 shares reported; filing documents a regulated resale.

The filing records a Rule 144 sale of 6,000 ordinary shares by Johannes Jacob Pieter Kastelein on 01/05/2026, with proceeds listed as $199,500. The notice serves as a transfer compliance disclosure rather than a company action.

Key dependencies include holding-period and volume conditions under Rule 144; timing and compliance specifics beyond the reported sale are not provided in the excerpt.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares, nominal value EUR 0.12 per share	ABN AMRO Gustav Mahlerlaan 10 Amsterdam P7 1082 PP	45481	1575007.03	114975422	02/20/2026	Nasdaq Global Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares, nominal value EUR 0.12 per share	03/26/2025	Vesting of RSU Grant	NewAmsterdam Pharma Company N.V.			45481	03/26/2025	RSU Vesting

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Johannes Jacob Pieter Kastelein Gooimeer 2-35 Naarden P7 1411 DC	Ordinary shares, nominal value EUR 0.12 per share	01/05/2026	6000	199500.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did NAMS report in this Form 144 filing?

It reports a Rule 144 sale of 6,000 ordinary shares by Johannes J. P. Kastelein on 01/05/2026. The filing lists proceeds of $199,500, indicating the transaction and required resale disclosure under federal securities rules.

Who is listed as the seller in the NAMS Form 144?

The seller is listed as Johannes Jacob Pieter Kastelein, with an address shown in Naarden. The form attributes the reported sale and provides the transaction date and proceeds amount for regulatory transparency.

How many shares and what dollar amount were reported sold?

The filing shows 6,000 ordinary shares sold for $199,500. Those figures appear on the Form 144 excerpt and reflect the reported quantity and gross proceeds of the resale transaction.

Does the Form 144 say the company received proceeds from the sale?

No specific statement assigns proceeds to the company; the form lists the seller and proceeds of $199,500. Rule 144 filings typically report reseller activity rather than company receipt of funds.

When did the RSU vesting noted in the excerpt occur for NAMS?

An RSU vesting event in the excerpt is dated 03/26/2025. The excerpt lists an RSU vesting for NewAmsterdam Pharma Company N.V., separate from the Rule 144 sale reported later.